Ken Griffin Zoetis Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$165.67 - $199.94 $30.1 Million - $36.3 Million	-181,700 Reduced 50.14%	180,700 $30.6 Million
Q4 2023 Feb 14, 2024	SELL	$151.44 - $200.09 $16.3 Million - $21.5 Million	-107,700 Reduced 22.91%	362,400 $71.5 Million
Q3 2023 Nov 14, 2023	BUY	$167.14 - $192.77 $27.7 Million - $31.9 Million	165,500 Added 54.33%	470,100 $81.8 Million
Q2 2023 Aug 14, 2023	SELL	$160.94 - $186.23 $44.3 Million - $51.2 Million	-275,000 Reduced 47.45%	304,600 $52.5 Million
Q1 2023 May 15, 2023	SELL	$145.48 - $175.02 $1.96 Million - $2.36 Million	-13,500 Reduced 2.28%	579,600 $96.5 Million

Q4 2022 Feb 14, 2023	BUY	$131.14 - $157.47 $32.3 Million - $38.8 Million	246,400 Added 71.07%	593,100 $86.9 Million
Q3 2022 Nov 14, 2022	SELL	$148.29 - $182.55 $71.4 Million - $87.9 Million	-481,600 Reduced 58.14%	346,700 $51.4 Million

1,859

416M

1.13M

1.81M

Ticker ZTS
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 468,139,008
Market Cap $81.9B
Description
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.